Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)†

(2012) P. C. Thuss-Patience et al.   ANNALS OF ONCOLOGY

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

(2012) Jung Hun Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer

(2011) Eliza Hawkes et al.   EUROPEAN JOURNAL OF CANCER

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

(2010) Jin Li et al.   BMC CANCER

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

(2010) Yung-Jue Bang et al.   INVESTIGATIONAL NEW DRUGS

Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study

(2009) Se Hoon Park et al.   ANTI-CANCER DRUGS